Inactivation of the apoptosis effector Apaf-1 in malignant melanoma

María S. Soengas, Paola Capodieci, David Polsky, Jaume Mora, Manel Esteller, Ximena Opitz-Araya, Richard McCombie, James G. Herman, William L. Gerald, Yuri A. Lazebnik, Carlos Cordón-Cardó, Scott W. Lowe

Research output: Contribution to journalArticle

Abstract

Metastatic melanoma is a deadly cancer that fails to respond to conventional chemotherapy and is poorly understood at the molecular level1. p53 mutations often occur in aggressive and chemoresistant cancers but are rarely observe in melanoma1.2. Here we show that metastatic melanomas often lose Apaf-1,a cell-death effector that acts with cytocrhome c and caspase-9 to mediate p53-dependent apoptosis3. Loss of Apaf-1 expression is accompanied by allelic loss in metastatic melanomas, but can be recovered in melanoma cell lines by treatment with the methylation inhibitor 5-aza-2' -deoxycytidine (5aza2dC). Apaf-1-negative melanomas are invariably chemoresistant and are unable to execute a typical apoptotic programme in response to p53 activation. Restoring physiological levels of Apaf-1 through gene transfer or 5aza2dC treatment markedly enhances chemosensivity and rescues the apoptotic defects associated with Apaf-1 loss. We conclude that Apaf-1 is inactivated in matastatic melanomas, which leads to defects in the execution of apoptotic cell death. Apaf-1 loss may contribute to the low frequency of p53 mutations observed in this highly chemoresistant tumour type.

Original languageEnglish (US)
Pages (from-to)207-211
Number of pages5
JournalNature
Volume409
Issue number6817
DOIs
StatePublished - Jan 11 2001

Fingerprint

Melanoma
decitabine
Apoptosis
Cell Death
Neoplasms
Caspase 9
Loss of Heterozygosity
Mutation Rate
Methylation
Drug Therapy
Cell Line
Mutation
Therapeutics
Genes

ASJC Scopus subject areas

  • General

Cite this

Soengas, M. S., Capodieci, P., Polsky, D., Mora, J., Esteller, M., Opitz-Araya, X., ... Lowe, S. W. (2001). Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature, 409(6817), 207-211. https://doi.org/10.1038/35051606

Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. / Soengas, María S.; Capodieci, Paola; Polsky, David; Mora, Jaume; Esteller, Manel; Opitz-Araya, Ximena; McCombie, Richard; Herman, James G.; Gerald, William L.; Lazebnik, Yuri A.; Cordón-Cardó, Carlos; Lowe, Scott W.

In: Nature, Vol. 409, No. 6817, 11.01.2001, p. 207-211.

Research output: Contribution to journalArticle

Soengas, MS, Capodieci, P, Polsky, D, Mora, J, Esteller, M, Opitz-Araya, X, McCombie, R, Herman, JG, Gerald, WL, Lazebnik, YA, Cordón-Cardó, C & Lowe, SW 2001, 'Inactivation of the apoptosis effector Apaf-1 in malignant melanoma', Nature, vol. 409, no. 6817, pp. 207-211. https://doi.org/10.1038/35051606
Soengas MS, Capodieci P, Polsky D, Mora J, Esteller M, Opitz-Araya X et al. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature. 2001 Jan 11;409(6817):207-211. https://doi.org/10.1038/35051606
Soengas, María S. ; Capodieci, Paola ; Polsky, David ; Mora, Jaume ; Esteller, Manel ; Opitz-Araya, Ximena ; McCombie, Richard ; Herman, James G. ; Gerald, William L. ; Lazebnik, Yuri A. ; Cordón-Cardó, Carlos ; Lowe, Scott W. / Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. In: Nature. 2001 ; Vol. 409, No. 6817. pp. 207-211.
@article{01ff7be311ca4e4ab58be98ee8fcbad9,
title = "Inactivation of the apoptosis effector Apaf-1 in malignant melanoma",
abstract = "Metastatic melanoma is a deadly cancer that fails to respond to conventional chemotherapy and is poorly understood at the molecular level1. p53 mutations often occur in aggressive and chemoresistant cancers but are rarely observe in melanoma1.2. Here we show that metastatic melanomas often lose Apaf-1,a cell-death effector that acts with cytocrhome c and caspase-9 to mediate p53-dependent apoptosis3. Loss of Apaf-1 expression is accompanied by allelic loss in metastatic melanomas, but can be recovered in melanoma cell lines by treatment with the methylation inhibitor 5-aza-2' -deoxycytidine (5aza2dC). Apaf-1-negative melanomas are invariably chemoresistant and are unable to execute a typical apoptotic programme in response to p53 activation. Restoring physiological levels of Apaf-1 through gene transfer or 5aza2dC treatment markedly enhances chemosensivity and rescues the apoptotic defects associated with Apaf-1 loss. We conclude that Apaf-1 is inactivated in matastatic melanomas, which leads to defects in the execution of apoptotic cell death. Apaf-1 loss may contribute to the low frequency of p53 mutations observed in this highly chemoresistant tumour type.",
author = "Soengas, {Mar{\'i}a S.} and Paola Capodieci and David Polsky and Jaume Mora and Manel Esteller and Ximena Opitz-Araya and Richard McCombie and Herman, {James G.} and Gerald, {William L.} and Lazebnik, {Yuri A.} and Carlos Cord{\'o}n-Card{\'o} and Lowe, {Scott W.}",
year = "2001",
month = "1",
day = "11",
doi = "10.1038/35051606",
language = "English (US)",
volume = "409",
pages = "207--211",
journal = "Nature",
issn = "0028-0836",
publisher = "Nature Publishing Group",
number = "6817",

}

TY - JOUR

T1 - Inactivation of the apoptosis effector Apaf-1 in malignant melanoma

AU - Soengas, María S.

AU - Capodieci, Paola

AU - Polsky, David

AU - Mora, Jaume

AU - Esteller, Manel

AU - Opitz-Araya, Ximena

AU - McCombie, Richard

AU - Herman, James G.

AU - Gerald, William L.

AU - Lazebnik, Yuri A.

AU - Cordón-Cardó, Carlos

AU - Lowe, Scott W.

PY - 2001/1/11

Y1 - 2001/1/11

N2 - Metastatic melanoma is a deadly cancer that fails to respond to conventional chemotherapy and is poorly understood at the molecular level1. p53 mutations often occur in aggressive and chemoresistant cancers but are rarely observe in melanoma1.2. Here we show that metastatic melanomas often lose Apaf-1,a cell-death effector that acts with cytocrhome c and caspase-9 to mediate p53-dependent apoptosis3. Loss of Apaf-1 expression is accompanied by allelic loss in metastatic melanomas, but can be recovered in melanoma cell lines by treatment with the methylation inhibitor 5-aza-2' -deoxycytidine (5aza2dC). Apaf-1-negative melanomas are invariably chemoresistant and are unable to execute a typical apoptotic programme in response to p53 activation. Restoring physiological levels of Apaf-1 through gene transfer or 5aza2dC treatment markedly enhances chemosensivity and rescues the apoptotic defects associated with Apaf-1 loss. We conclude that Apaf-1 is inactivated in matastatic melanomas, which leads to defects in the execution of apoptotic cell death. Apaf-1 loss may contribute to the low frequency of p53 mutations observed in this highly chemoresistant tumour type.

AB - Metastatic melanoma is a deadly cancer that fails to respond to conventional chemotherapy and is poorly understood at the molecular level1. p53 mutations often occur in aggressive and chemoresistant cancers but are rarely observe in melanoma1.2. Here we show that metastatic melanomas often lose Apaf-1,a cell-death effector that acts with cytocrhome c and caspase-9 to mediate p53-dependent apoptosis3. Loss of Apaf-1 expression is accompanied by allelic loss in metastatic melanomas, but can be recovered in melanoma cell lines by treatment with the methylation inhibitor 5-aza-2' -deoxycytidine (5aza2dC). Apaf-1-negative melanomas are invariably chemoresistant and are unable to execute a typical apoptotic programme in response to p53 activation. Restoring physiological levels of Apaf-1 through gene transfer or 5aza2dC treatment markedly enhances chemosensivity and rescues the apoptotic defects associated with Apaf-1 loss. We conclude that Apaf-1 is inactivated in matastatic melanomas, which leads to defects in the execution of apoptotic cell death. Apaf-1 loss may contribute to the low frequency of p53 mutations observed in this highly chemoresistant tumour type.

UR - http://www.scopus.com/inward/record.url?scp=0035843169&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035843169&partnerID=8YFLogxK

U2 - 10.1038/35051606

DO - 10.1038/35051606

M3 - Article

C2 - 11196646

AN - SCOPUS:0035843169

VL - 409

SP - 207

EP - 211

JO - Nature

JF - Nature

SN - 0028-0836

IS - 6817

ER -